Pembrolizumab for cisplatin-failure recurrent/metastatic head and neck squamous cell carcinoma

被引：0
|
作者：
Chen, W-C. [1 ]
Chang, P. M-H. [2 ]
Lee, Y-T. [3 ]
Lu, W-B. [4 ]
Yang, M-H. [2 ]
机构：
[1] Taipei Vet Gen Hosp, Med, Taipei, Taiwan
[2] Taipei Vet Gen Hosp, Dept Oncol, Taipei, Taiwan
[3] Taipei Vet Gen Hosp, Dept Med, Taipei, Taiwan
[4] Changzhou Wujin Peoples Hosp, Dept Med Oncol, Changzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
385P
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck
    Vermorken, J. B.
    Licitra, L.
    Stoehlmacher-Williams, J.
    Dietz, A.
    Lopez-Picazo, J. M.
    Hamid, O.
    Hossain, A. M.
    Chang, S. -C.
    Gauler, T. C.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 (13) : 2877 - 2883
  • [42] Palliative chemotherapy with cisplatin (C) and ifosfamide (I) for recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).
    Fernández, A
    Mesía, R
    Montes, A
    Cardenal, F
    Montes, A
    García, M
    Dotor, E
    Muñoz, M
    Juan, A
    Monner, A
    Galiana, R
    [J]. EUROPEAN JOURNAL OF CANCER, 1999, 35 : S68 - S68
  • [43] Prognostic significance of metastatic sites in recurrent or metastatic squamous cell carcinoma of the head and neck
    Nishimura, Ari
    Yokota, Tomoya
    Iida, Yoshiyuki
    Kamijo, Tomoyuki
    Mukaigawa, Takashi
    Onozawa, Yusuke
    Todaka, Akiko
    Hamauchi, Satoshi
    Kawakami, Takeshi
    Shirasu, Hiromichi
    Onoe, Tsuyoshi
    Ogawa, Hirohumi
    Kawabata, Takanori
    Yasui, Hirofumi
    Onitsuka, Tetsuro
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S296 - S296
  • [44] Pembrolizumab vs the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Cost-Effectiveness Analysis
    Lang, Yitian
    Dong, Deshi
    Wu, Bin
    [J]. CLINICAL DRUG INVESTIGATION, 2020, 40 (12) : 1137 - 1146
  • [45] Pembrolizumab vs the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Cost-Effectiveness Analysis
    Yitian Lang
    Deshi Dong
    Bin Wu
    [J]. Clinical Drug Investigation, 2020, 40 : 1137 - 1146
  • [46] Cost-effectiveness analysis of nivolumab compared to pembrolizumab in the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck
    Yeh, Justin
    Guddati, Achuta Kumar
    [J]. AMERICAN JOURNAL OF CANCER RESEARCH, 2020, 10 (06): : 1821 - 1826
  • [47] A phase II trial of pembrolizumab and cabozantinib in patients (pts) with recurrent metastatic head and neck squamous cell carcinoma (RMHNSCC).
    Saba, Nabil F.
    Ekpenyong, Asari
    McCook-Veal, Ashley
    Patel, Mihir
    Schmitt, Nicole Cherie
    Stokes, William A.
    Bates, James Edward
    Rudra, Soumon
    Abousaud, Marin Ibrahim
    Muzaffar, Jameel
    Kirtane, Kedar
    Teng, Yong
    Steuer, Conor Ernst
    Shin, Dong Moon
    Liu, Yuan
    Chung, Christine H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [48] Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: Hypothesis coming from the subgroup analysis
    De Felice, Francesca
    Bossi, Paolo
    [J]. ORAL ONCOLOGY, 2023, 137
  • [49] Platinum/taxane/pembrolizumab vs platinum/5FU/pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (r/mHNSCC)
    Prithviraj, T.
    [J]. ORAL ONCOLOGY, 2024, 158
  • [50] Recurrent head and neck squamous cell carcinoma
    Wu, S-Y.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
12345